Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study.

de Vries, F; Pouwels, S; Lammers, J; Leufkens, H; Bracke, M; Cooper, C; van Staa, T

Journal article

Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study.

Abstract:: BACKGROUND: Patients using higher dosages of inhaled or oral glucocorticoids (GCs) have an increased risk of hip/femur fractures. The role of the underlying disease in the aetiology of this increased risk has not been widely studied. OBJECTIVE: To evaluate the contribution of the underlying disease to the risk of hip/femur fracture in patients using inhaled or oral GCs. DESIGN AND SUBJECTS: A case-control study within the Dutch PHARMO-RLS database was conducted. Cases (n = 6763) were adult patients with a first hip/femur fracture during enrolment. Each case was matched to four controls by age, gender and region. RESULTS: The risk of hip/femur fracture increased with current use of inhaled GCs (crude OR 1.30, 95% CI:1.16-1.47) and with current use of oral GCs (crude OR 1.66, 95% CI: 1.46-1.90). After adjustment for disease severity, the risk of hip/femur fracture was no longer statistically significantly increased in inhaled GC users (adjusted OR 1.08, 95% CI: 0.91-1.27), whilst it remained elevated in oral GC users (adjusted OR 1.43, 95% CI: 1.22-1.67). Patients using inhaled GCs without any exposure to oral GCs had no increased risk of fracture (adjusted OR 0.98, 95% CI: 0.79-1.22). CONCLUSION: Inhaled GC users had no increased risk of femur/hip fracture after adjustment for underlying disease severity. Our data suggest that, even at higher dosages, inhaled GC use is not an independent risk factor for fracture. In contrast, oral GC use was associated with an increased risk of fracture, which was not fully explained by the underlying disease severity.

Publication status:: Published

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

de Vries, F., Pouwels, S., Lammers, J., Leufkens, H., Bracke, M., Cooper, C., & van Staa, T. (2007). Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. Journal of Internal Medicine, 261(2), 170–177.

MLA Style

de Vries, F., et al. “Use of Inhaled and Oral Glucocorticoids, Severity of Inflammatory Disease and Risk of Hip/Femur Fracture: a Population-Based Case-Control Study.” Journal of Internal Medicine, vol. 261, no. 2, 2007, pp. 170–77.

Chicago Style

Vries, F de, S Pouwels, J Lammers, H Leufkens, M Bracke, C Cooper, and T van Staa. 2007. “Use of Inhaled and Oral Glucocorticoids, Severity of Inflammatory Disease and Risk of Hip/Femur Fracture: a Population-Based Case-Control Study.” Journal of Internal Medicine 261 (2): 170–77.
Share
Print